arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2008-14-3-288-293arthyper-1243Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL TRIALSРезультаты исследования ADVANCE - движение вперед в лечении артериальной гипертонии и сахарного диабетаResults of ADVAVCE study -
an advance in the treatment of hypertension and diabetes
mellitusКарповЮ.KarpovY.noemail@neicon.ruФГУ РКНПК РосмедтехнологийРоссияRussian cardiac sciense complexRussian Federation200828062008143288293Copyright © Карпов
Ю., 20082008Карпов
Ю.Karpov
Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1243Referencesdler A., Stratton I.M., Neil H., et al. Association of systolic blood pressure with macrovascular and micro vascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.dler A., Stratton I.M., Neil H., et al. Association of systolic blood pressure with macrovascular and micro vascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-1187.The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007; 28: 88-136.The Task Force on Diabetes and Cardiovascular Disease of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007; 28: 88-136.Stratton I.M., Adler A.L., Neil H.A. et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.Stratton I.M., Adler A.L., Neil H.A. et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.The ADVANCE Collaborative Group: Rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with Type 2 diabetes mellitus. J Hypertens 2001; 19: 21-28.The ADVANCE Collaborative Group: Rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with Type 2 diabetes mellitus. J Hypertens 2001; 19: 21-28.ADVANCE Collaborative Group/ ADVANCE - Action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet./ Med./ 2005; 1-7.ADVANCE Collaborative Group/ ADVANCE - Action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet./ Med./ 2005; 1-7.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-840.ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828-840.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.Yeon SS, Nesto RW. Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials. Rev Cardiovasc Med 2008;9(1):l-4.Yeon SS, Nesto RW. Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials. Rev Cardiovasc Med 2008;9(1):l-4.Cefalu WT, Watson K. Intensive glycemic control and cardiovascular disease. Observations from the ACCORD study. Diabetes 2008; 57: 1163-1165.Cefalu WT, Watson K. Intensive glycemic control and cardiovascular disease. Observations from the ACCORD study. Diabetes 2008; 57: 1163-1165.Goede P, Lund-Andersen H, Parving HH, et al. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-589.Goede P, Lund-Andersen H, Parving HH, et al. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-589.Holman RR, Paul SJ, Bethel MA, et al. Ten-year follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; [ Epub ahead of print].Holman RR, Paul SJ, Bethel MA, et al. Ten-year follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; [ Epub ahead of print].Chalmers J. ADVANCE: new results. EASD 2008 Meeting, September 8. Oral presentation.Chalmers J. ADVANCE: new results. EASD 2008 Meeting, September 8. Oral presentation.
The authors declare that there are no conflicts of interest present.